... fever with low blood counts Guillain-Barré syndrome Heart failure Blood clots Rare Side Effects of LynozyficLynozyfic includes a box warning — the FDA’s most serious type of warning — for serious side effects including: Cytokine release syndrome Damage to the nervous system, including ICANS Because of the risk of adverse effects, Lynozyfic, along with Elrexfio ...
... fever with low blood counts Guillain-Barré syndrome Heart failure Blood clots Rare Side Effects of LynozyficLynozyfic includes a box warning — the FDA’s most serious type of warning — for serious side effects including: Cytokine release syndrome Damage to the nervous system, including ICANS Because of the risk of adverse effects, Lynozyfic, along with Elrexfio ...
... From Therapeutic Innovations for US Patients With Relapsed/Refractory Multiple Myeloma — Therapeutic Advances in Hematology Multiple Myeloma With High-Risk Cytogenetics and Its Treatment Approach — International Journal of Hematology FDA DISCO Burst Edition: FDA Approvals of Talvey (Talquetamab-Tgvs) for Relapsed or Refractory Multiple Myeloma, and Elrexfio ...
... From Therapeutic Innovations for US Patients With Relapsed/Refractory Multiple Myeloma — Therapeutic Advances in Hematology Multiple Myeloma With High-Risk Cytogenetics and Its Treatment Approach — International Journal of Hematology FDA DISCO Burst Edition: FDA Approvals of Talvey (Talquetamab-Tgvs) for Relapsed or Refractory Multiple Myeloma, and Elrexfio ...
... Examples include elranatamab (Elrexfio), teclistamab (Tecvayli), talquetamab (Talvey), and linvoseltamab-gcpt (Lynozyfic). Nuclear export inhibitors — These drugs block XPO1, a protein that helps cancer cells survive. Selinexor (Xpovio) is the first FDA-approved XPO1 inhibitor, preventing this process and causing cancer cell death. ...
... Examples include elranatamab (Elrexfio), teclistamab (Tecvayli), talquetamab (Talvey), and linvoseltamab-gcpt (Lynozyfic). Nuclear export inhibitors — These drugs block XPO1, a protein that helps cancer cells survive. Selinexor (Xpovio) is the first FDA-approved XPO1 inhibitor, preventing this process and causing cancer cell death. ...
... Sarclisa), which can recognize and attack myeloma cells Chimeric antigen receptor (CAR) T-cell therapy, which modifies a person’s T cells to better target myeloma cells Teclistamab-cqyv (Tecvayli), the first bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, which helps T cells find and destroy myeloma cells Elranatamab-bcmm (Elrexfio ...
... Sarclisa), which can recognize and attack myeloma cells Chimeric antigen receptor (CAR) T-cell therapy, which modifies a person’s T cells to better target myeloma cells Teclistamab-cqyv (Tecvayli), the first bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, which helps T cells find and destroy myeloma cells Elranatamab-bcmm (Elrexfio ...
... Since then, the FDA has approved three new BiTES: elranatamab-bccm (Elrexfio), talquetamab (Talvey), and linvoseltamab-gcpt (Lynozyfic).Read more about bispecific T-cell engagers and how they work to treat relapsed or refractory multiple myeloma.6. ...
... Since then, the FDA has approved three new BiTES: elranatamab-bccm (Elrexfio), talquetamab (Talvey), and linvoseltamab-gcpt (Lynozyfic).Read more about bispecific T-cell engagers and how they work to treat relapsed or refractory multiple myeloma.6. ...
... refractory multiple myeloma.In 2019, the FDA approved selinexor (Xpovio), offering a new mechanism of action as a selective inhibitor of nuclear export.The approval of isatuximab-irfc (Sarclisa) in 2020, along with newer bispecific T-cell engagers like teclistamab-cqyv (Tecvayli, approved in 2022), as well as talquetamab-tgvs (Talvey) and elranatamab-bcmm (Elrexfio ...
... refractory multiple myeloma.In 2019, the FDA approved selinexor (Xpovio), offering a new mechanism of action as a selective inhibitor of nuclear export.The approval of isatuximab-irfc (Sarclisa) in 2020, along with newer bispecific T-cell engagers like teclistamab-cqyv (Tecvayli, approved in 2022), as well as talquetamab-tgvs (Talvey) and elranatamab-bcmm (Elrexfio ...
... As of July 2025, four bispecific antibodies — elranatamab-bcmm (Elrexfio), talquetamab (Talvey), teclistamab-cqyv (Tecvayli), and linvoseltamab-gcpt (Lynozyfic) — have been approved for myeloma. ...
... As of July 2025, four bispecific antibodies — elranatamab-bcmm (Elrexfio), talquetamab (Talvey), teclistamab-cqyv (Tecvayli), and linvoseltamab-gcpt (Lynozyfic) — have been approved for myeloma. ...
... Elranatamab-bcmm, sold under the brand name Elrexfio, is a BCMA bispecific antibody approved by the FDA in August 2023.7. CAR T-Cell TherapiesTwo BCMA-targeted antibodies are used in a type of treatment known as chimeric antigen receptor (CAR) T-cell therapy, which involves teaching the immune system’s T cells to attack myeloma cells. ...
... Elranatamab-bcmm, sold under the brand name Elrexfio, is a BCMA bispecific antibody approved by the FDA in August 2023.7. CAR T-Cell TherapiesTwo BCMA-targeted antibodies are used in a type of treatment known as chimeric antigen receptor (CAR) T-cell therapy, which involves teaching the immune system’s T cells to attack myeloma cells. ...
... As a result, teclistamab-cqyv causes tumor-cell lysis (destruction).Other bispecific T-cell engagers sometimes used to treat myeloma are talquetamab-tgvs (Talvey), elranatamab-bcmm (Elrexfio), and linvoseltamab-gcpt (Lynozyfic).6. Targeted TherapiesTargeted therapies limit how much cancer cells can divide, multiply, and spread. ...
... As a result, teclistamab-cqyv causes tumor-cell lysis (destruction).Other bispecific T-cell engagers sometimes used to treat myeloma are talquetamab-tgvs (Talvey), elranatamab-bcmm (Elrexfio), and linvoseltamab-gcpt (Lynozyfic).6. Targeted TherapiesTargeted therapies limit how much cancer cells can divide, multiply, and spread. ...
Join